ACCESSWIRE

3852 articles with ACCESSWIRE

• Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors

  2/9/2021

  RELIEF THERAPEUTICS Holding AG announces the resignation, effective immediately, of Board of Directors member Thomaz Burckhardt.

• Core One Labs Announces Adding Video Conference Capabilities to Teleconference Call Scheduled for February 10, 2021 1:30 p.m. PST/4:30 p.m. EST

  2/9/2021

  Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt::LD62) (WKN: A2P8K3) is pleased to announce that it has added video conference capabilities to its previously announced teleconference call scheduled for Wednesday, February 10, 2021 at 1:30 p.m. PST, 4:30 p.m. EST and 10:30 p.m. CET, with Dr. Robert E.W. Hancock, Chairman and Joel Shacker, CEO to discuss development and strategy.

• Utah Medical Products, Inc. Announces Quarterly Dividend payable on April 2, 2021

  2/9/2021

  Utah Medical Products, Inc. announces that its Board of Directors approved a quarterly cash dividend of twenty-eight and one-half cents per share of common stock payable on April 2, 2021 to shareholders of record at the close of business on March 17, 2021.

• OPTEC International Adds Pandemic 10 Minute Rapid-Test Kits To PPE Distribution Network

  2/9/2021

  OPTEC International, Inc., a developer of UV and UV-C safety products using related advanced technologies specific to Personal Protection Equipment, announced the addition of Antigen & Antibody Rapid-Test Kits with highly accurate results in 10 Minutes to the company's PPE Inventory for global distribution.

• MediXall Group Launches Health Karma for Employers to Accelerate Delivery of Healthcare

  2/9/2021

  MediXall Group, Inc., a healthcare technology company, announced it has launched Health Karma for Employers, a health services platform that provides millions of businesses with the ability to offer affordable, high-quality healthcare benefits to their employees, whether they are eligible for health insurance coverage or not.

• Evotec And Related Sciences Enter Integrated Drug Discovery and Development Partnership

  2/9/2021

  Evotec SE announced that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.

• Asia Green Biotechnology Corp. Expands Technology Development Relationship with Pathway Rx Inc. and Swysh Inc. with Agreement to Undertake Initial Toxicity Testing for Migraine Study

  2/9/2021

  Asia Green Biotechnology Corp. is pleased to announce that it has entered an agreement with Pathway Rx Inc. and Swysh Inc. pursuant to which AGB has expanded its commitment to assist in the develop and commercialize the Cannabis sativa varieties to which Pathway Rx Inc.

• Applied UV Announces Acquisition of the Airocide(R) Technology Platform for Airborne Pathogen Reduction

  2/9/2021

  Applied UV, Inc. announced it has closed on the acquisition by its wholly-owned subsidiary, SteriLumen, Inc., of substantially all of the assets of Akida Holdings LLC, including all of the rights to manufacture and sell the Airocide® System of patented, air disinfection and purification technologies, for 1.375 million common shares of Applied UV stock and $901,274.96 in cash.

• Antev Appoints Amit Kohli as Chief Executive Officer

  2/9/2021

  Antev Ltd , a late clinical-stage drug development company advancing the drug teverelix to treat prostate cancer and related indications, today announces the appointment of Amit Kohli as Chief Executive Officer

• NanoViricides’s Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies

  2/8/2021

  NanoViricides, Inc. has announced today that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections was well tolerated in safety pharmacology studies required for progressing to human clinical trials.

• SunTech Medical and Valencell Announce Proof of Concept for DeltaTrak(TM) Blood Pressure, a Major Advancement in BP Technology

  2/8/2021

  SunTech Medical Inc., the leading provider of clinical-grade blood pressure (BP) measurement technologies and devices, and Valencell Inc., the leader in highly accurate biometric sensors for wearables, today announce proof of concept for DeltaTrak technology.

• RepliCel CEO Provides Corporate Update

  2/8/2021

  Targets for 2021 include dermal injector commercial launch, new partnerships, new innovation initiatives, and launch of more clinical testing

• Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response

  2/8/2021

  ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the National and Kapodistrian University of Athens has published results of a new study undertaken in non-small cell lung cancer.

• Core One Labs Engages Donohoe Advisory for Nasdaq Listing and Schedules Special Investor Call with Dr. Robert E.W. Hancock to Demonstrate Recent Research Outcome

  2/6/2021

  Core One Labs Inc. announces that it has engaged Donohoe Advisory Associates LLC in connection with its efforts to seek a listing for its common shares on a NASDAQ Stock Market.

• Prevacus Announces Sale of PRV-002 to Odyssey Group International

  2/5/2021

  Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders; today announced that it has entered into a definitive agreement for the sale of drug candidate PRV-002 to Odyssey Group International (OTCQB:ODYY).

• CureVac to Host Conference Call on COVID-19 Partnership Update on February 5, 2021

  2/5/2021

  CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, will host a conference call and webcast on , Friday February 5, 2021 at 4:00 p.m. CET / 10:00 a.m. EST.

• CureVac and UK Government to Collaborate on Development of Vaccines Against SARS-CoV-2 Variants

  2/5/2021

  - Collaboration combines expertise, resources and technology from both parties to develop and manufacture variant vaccines for commercial supply and distribution in the UK and its territories - Objective is to mitigate the effects of the current pandemic and to help manage future outbreaks by forming a rapid response unit leveraging the unique strengths of CureVacs mRNA platform

• NeoGenomics Schedules its Fourth Quarter and Full Year 2020 Earnings Release for February 24, 2021

  2/5/2021

  NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021.

• Molecular Partners Reports Corporate Highlights from Q4 2020 and Key Financials for FY2020

  2/5/2021

  Announced positive safety data from first dose cohort of ongoing phase 1 COVID-19 study which is on track to report data from all cohorts in Q1 2021

• UTILITY Therapeutics Announces Capital Raise and 2021 Corporate Objectives

  2/4/2021

  Financing from new and existing investors to advance two European-approved antibiotics for the U.S. market Pivmecillinam Pre-NDA meeting with the FDA scheduled for April 2021 LONDON, UK / ACCESSWIRE / February 4, 2021 / UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), announced the completion of a capital raise and provided corporate objecti